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Abstract 
 
Introduction: Drug use during pregnancy should be carefully analysed in order to try to 
establish safe practice and avoid usage of dangerous substances. There is little or no evidence 
for safe use in pregnancy in relation to many habitually used drugs however, recent studies 
have shown elevated levels of drug usage among pregnant women.  
 
Objective: To assess the prevalence of drug use before and during pregnancy and to estimate 
the maternal determinants of such use among mothers of the Generation XXI birth cohort. 
 
Methods: The present study is based on the Generation XXI cohort, which included 8647 
newborns, whose mothers (8495) were recruited at delivery from April 2005 to August 2006 
in one of the five public maternity units that cover six municipalities of the metropolitan area 
of Porto, Portugal. Information on social and demographic characteristics, obstetric and 
gynecological history, lifestyles and current pregnancy events was obtained using a structured 
questionnaire during the hospital stay (24-72 hours after the delivery) by trained interviewers. 
Through this survey we were able to collect information regarding drug use three month 
before and during pregnancy. All the drugs were classified according to the Anatomical 
Therapeutic Chemical Classification System (ATC) from the World Health Organization 
(WHO) and US Food and Drug Administration (FDA) risk classification system. In order to 
classify the drugs according to the FDA we used Infarmed publications from December 2004 
and August 2011. 
 
Results: The prevalence of overall drug use before conception and during pregnancy was 
respectively 49.2% and 98.3%. In both time periods, 30.8% of women took drugs. Excluding 
supplements (ATC A11, A12 and B03), the prevalence of drug use before, during pregnancy 
and in both time periods decreased to 34.9%, 60.2% and 15.3%, respectively. Before 
pregnancy, 5537 drugs were reported by women while, during the pregnancy this number 
increased to 27775. In accordance with the ATC system classification the most common 
preconception drugs used were from category G and B (22.8% and 19.1% of women took at 
least one drug from these categories). During pregnancy, 95.4% of women reported having 
used drugs from category B, 66.4% from category A, 19.7% from category N and 16.4% from 
category J. During pregnancy and according to the 2011 Infarmed publication (based on FDA 
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classification system), drugs from category A and category B were used by 91.6% and 29.0% 
of women respectively. Category C was used by 18.9% of the women and category D and X 
were taken by 8.7% and 0.2% of women respectively. When the 2004 Infarmed publication 
was used to classify the drugs, the percentage of use for category C and D decreased 
respectively to 9.1% and 6.8%. Category X remained the same in both publications. Before 
pregnancy and after adjusting the models, more educated women, primiparous women and 
those who had chronic diseases were more likely to have used drugs. Excluding supplements, 
the educational level and parity were no longer associated with drug use, however having 
reported chronic diseases remained associated in the same way as stated above. Women who 
lived with a partner were less likely to have used drugs, while those who had not planned the 
current pregnancy and had smoked before pregnancy were more likely to have used drugs. 
During pregnancy and after adjusting the models, the use of drugs was less likely to occur in 
less educated women, those who smoked before pregnancy and in those who were 
housewives or unemployed. Women, who chose private prenatal care, had more appointments 
and complications during pregnancy were more likely to have used drugs. After excluding 
supplements, women with chronic diseases and those who did not plan the current pregnancy 
were more likely to use drugs. The working condition and the health care system were no 
longer associated with drug use.  
 
Conclusion: According to our findings, whether we include supplements or not, there is an 
evident tendency for a greater use of drugs during pregnancy when comparing with the three 
months before pregnancy. Drug use during pregnancy by women was very common; however, 
according to the FDA classification system the proportion of women who used drugs from 
category D and X was low. Before pregnancy, the use of drugs was associated with the 
existence of a chronic condition. The use of drugs prior to pregnancy was linked with better 
social profiles when the supplements were included, while when they were excluded, it was 
associated with worse profiles. During pregnancy, despite the universal use of medicines, 
similar patterns were observed. These studies are essential for creating prescription guidelines 
during pregnancy in order to improve medical care. 
